Filter
614
Text search:
FDA
Featured
81
121
Language
Document type
303
160
75
24
24
13
7
3
2
2
1
Countries
29
17
17
17
12
12
9
9
8
8
8
8
7
7
7
7
7
7
6
6
6
6
6
6
6
5
5
5
5
4
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
190
80
22
17
11
7
2
Toolboxes
136
69
59
48
35
30
28
17
13
10
8
7
7
6
3
3
3
3
2
1
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i
...
A survival guide for clinicans.
3rd edition.
The use of Delamanid and Bedaquiline for Children with Drug-Resistant Tuberculosis.
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.
Division of Tuberculosis Elimination.
The intent of these guidelines is to develop a holistic, coordinated, proactive and technology driven strategy for management of biological disasters through a culture of prevention, mitigation and preparedness to generate a prompt and effective response in the event of an emergency. Th
...
Therapeutics Information and Pharmacovigilance Centre | TIPC
This guideline is intended to provide recommendations to applicants wishing to submit applications for the registration of medicines. It represents the Medicines Control Council’s current thinking on the safety, quality and efficacy of medicines.
Ensuring Access to Simple, Safe and Effective First-Line Medicines for Tuberculosis.
Accessed in November 2017.
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
Division of Global Migration and Quarantine
April 16, 2012
Morbidity and Mortality Weekly Report
Recommendations and Reports: July 7, 2006 / Vol. 55 / No. RR-9
